Apoptosis

Signaling pathways in pancreatic cancer pathogenesis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Conventional and investigational cancer therapies have had little to no effect on the course of pancreatic cancer disease progression. Because apoptosis plays a major role in the effects of conventional chemo- and radiotherapy, it has been widely assumed that apoptotic pathways must be disrupted more frequently in pancreatic cancer than they are in other solid malignancies. However, comprehensive genomic characterizations of primary pancreatic cancers do not support this conclusion. Rather, it appears that one of the recently identified molecular subtypes of pancreatic cancer (quasimesenchymal/basal-like/squamous) that shares similarities with basal-like breast and bladder cancers contains tumors that are most likely to be apoptosis sensitive and responsive to conventional chemotherapy. Otherwise it is not immediately obvious how the molecular and genomic properties of pancreatic cancers would be expected to impart apoptosis resistance, providing indirect but strong support for the conclusions that late diagnosis and the extent to which tumor-stromal interactions reinforce apoptosis resistance represent the truly unique challenges to effective clinical control of the disease. This book chapter will provide an update of what has been learned recently about the molecular control of apoptosis in pancreatic cancer and how the information might be exploited in the design of more effective therapeutic regimens.

Original languageEnglish (US)
Title of host publicationPancreatic Cancer
PublisherSpringer New York
Pages369-382
Number of pages14
ISBN (Electronic)9781493971930
ISBN (Print)9781493971916
DOIs
StatePublished - Apr 11 2018

Fingerprint

Pancreatic Neoplasms
Apoptosis
Neoplasms
Drug Therapy
Pancreatic Diseases
Investigational Therapies
Delayed Diagnosis
Urinary Bladder Neoplasms
Disease Progression
Radiotherapy
Breast Neoplasms

Keywords

  • BCL-2 family
  • Cancer-associated fibroblasts
  • EMT
  • IAPs
  • NFΚB
  • Stellate cells
  • Subtypes

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Apoptosis : Signaling pathways in pancreatic cancer pathogenesis. / McConkey, David; Choi, Woonyoung.

Pancreatic Cancer. Springer New York, 2018. p. 369-382.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{ccd84deeb57041f39549fcb9097e0531,
title = "Apoptosis: Signaling pathways in pancreatic cancer pathogenesis",
abstract = "Conventional and investigational cancer therapies have had little to no effect on the course of pancreatic cancer disease progression. Because apoptosis plays a major role in the effects of conventional chemo- and radiotherapy, it has been widely assumed that apoptotic pathways must be disrupted more frequently in pancreatic cancer than they are in other solid malignancies. However, comprehensive genomic characterizations of primary pancreatic cancers do not support this conclusion. Rather, it appears that one of the recently identified molecular subtypes of pancreatic cancer (quasimesenchymal/basal-like/squamous) that shares similarities with basal-like breast and bladder cancers contains tumors that are most likely to be apoptosis sensitive and responsive to conventional chemotherapy. Otherwise it is not immediately obvious how the molecular and genomic properties of pancreatic cancers would be expected to impart apoptosis resistance, providing indirect but strong support for the conclusions that late diagnosis and the extent to which tumor-stromal interactions reinforce apoptosis resistance represent the truly unique challenges to effective clinical control of the disease. This book chapter will provide an update of what has been learned recently about the molecular control of apoptosis in pancreatic cancer and how the information might be exploited in the design of more effective therapeutic regimens.",
keywords = "BCL-2 family, Cancer-associated fibroblasts, EMT, IAPs, NFΚB, Stellate cells, Subtypes",
author = "David McConkey and Woonyoung Choi",
year = "2018",
month = "4",
day = "11",
doi = "10.1007/978-1-4939-7193-0_14",
language = "English (US)",
isbn = "9781493971916",
pages = "369--382",
booktitle = "Pancreatic Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Apoptosis

T2 - Signaling pathways in pancreatic cancer pathogenesis

AU - McConkey, David

AU - Choi, Woonyoung

PY - 2018/4/11

Y1 - 2018/4/11

N2 - Conventional and investigational cancer therapies have had little to no effect on the course of pancreatic cancer disease progression. Because apoptosis plays a major role in the effects of conventional chemo- and radiotherapy, it has been widely assumed that apoptotic pathways must be disrupted more frequently in pancreatic cancer than they are in other solid malignancies. However, comprehensive genomic characterizations of primary pancreatic cancers do not support this conclusion. Rather, it appears that one of the recently identified molecular subtypes of pancreatic cancer (quasimesenchymal/basal-like/squamous) that shares similarities with basal-like breast and bladder cancers contains tumors that are most likely to be apoptosis sensitive and responsive to conventional chemotherapy. Otherwise it is not immediately obvious how the molecular and genomic properties of pancreatic cancers would be expected to impart apoptosis resistance, providing indirect but strong support for the conclusions that late diagnosis and the extent to which tumor-stromal interactions reinforce apoptosis resistance represent the truly unique challenges to effective clinical control of the disease. This book chapter will provide an update of what has been learned recently about the molecular control of apoptosis in pancreatic cancer and how the information might be exploited in the design of more effective therapeutic regimens.

AB - Conventional and investigational cancer therapies have had little to no effect on the course of pancreatic cancer disease progression. Because apoptosis plays a major role in the effects of conventional chemo- and radiotherapy, it has been widely assumed that apoptotic pathways must be disrupted more frequently in pancreatic cancer than they are in other solid malignancies. However, comprehensive genomic characterizations of primary pancreatic cancers do not support this conclusion. Rather, it appears that one of the recently identified molecular subtypes of pancreatic cancer (quasimesenchymal/basal-like/squamous) that shares similarities with basal-like breast and bladder cancers contains tumors that are most likely to be apoptosis sensitive and responsive to conventional chemotherapy. Otherwise it is not immediately obvious how the molecular and genomic properties of pancreatic cancers would be expected to impart apoptosis resistance, providing indirect but strong support for the conclusions that late diagnosis and the extent to which tumor-stromal interactions reinforce apoptosis resistance represent the truly unique challenges to effective clinical control of the disease. This book chapter will provide an update of what has been learned recently about the molecular control of apoptosis in pancreatic cancer and how the information might be exploited in the design of more effective therapeutic regimens.

KW - BCL-2 family

KW - Cancer-associated fibroblasts

KW - EMT

KW - IAPs

KW - NFΚB

KW - Stellate cells

KW - Subtypes

UR - http://www.scopus.com/inward/record.url?scp=84882748785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882748785&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7193-0_14

DO - 10.1007/978-1-4939-7193-0_14

M3 - Chapter

SN - 9781493971916

SP - 369

EP - 382

BT - Pancreatic Cancer

PB - Springer New York

ER -